Who are Terlipressin plus standard care's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lysipressin, Vasopressin intravenous infusion, vasopressin - early initiation, DDAVP, DDAVP Inhalant Product, desmopressin MELT formulation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/terlipressin-plus-standard-care.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Terlipressin plus standard care — Competitive Intelligence Brief

Terlipressin plus standard care (Terlipressin plus standard care) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressin analogue. Area: Cardiovascular.

phase 3 Vasopressin analogue Vasopressin receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Terlipressin plus standard care (Terlipressin plus standard care) — Shanghai Zhongshan Hospital. Terlipressin is a synthetic analogue of vasopressin that acts as a potent vasoconstrictor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Terlipressin plus standard care TARGET	Terlipressin plus standard care	Shanghai Zhongshan Hospital	phase 3	Vasopressin analogue	Vasopressin receptor
Lysipressin	LYPRESSIN	Novartis	marketed	lypressin	Vasopressin receptor	1982-01-01
Vasopressin intravenous infusion	Vasopressin intravenous infusion	University of Sao Paulo	marketed	Vasopressor agent; antidiuretic hormone	Vasopressin receptor V1a, V1b, and V2
vasopressin - early initiation	vasopressin - early initiation	The Cleveland Clinic	marketed	Vasopressor agent	Vasopressin receptor (V1 and V2)
DDAVP	DDAVP	Chang, Steve S., M.D.	marketed	Vasopressin receptor agonist	V2 vasopressin receptor (AVPR2)
DDAVP Inhalant Product	DDAVP Inhalant Product	Nationwide Children's Hospital	marketed	Vasopressin analog; antidiuretic agent	V2 vasopressin receptor; V1 vasopressin receptor
desmopressin MELT formulation	desmopressin MELT formulation	University Hospital, Ghent	marketed	Vasopressin analog / Antidiuretic agent	V2 vasopressin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressin analogue class)

Aga Khan University · 1 drug in this class
Shanghai Zhongshan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Terlipressin plus standard care — Competitive Intelligence Brief. https://druglandscape.com/ci/terlipressin-plus-standard-care. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab